Colleagues at the University of Salford provided two novel anti-cancer compounds for evaluation of drug-induced biochemical changes at the cellular level: PL63, which is a DNA cross-linking agent and analogue of the commercial anti-cancer drug busulfan [49], and YA1, which is a protein kinase inhibitor [50]. Here, WEE1 is linked to cancer.